ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

On October 3, 2025 ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, reported updated data from its Phase 2 ASPEN-06 (NCT05002127) trial will be presented during a poster session at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 40th Annual Meeting taking place November 5–9, 2025, in National Harbor, Maryland (Press release, ALX Oncology, OCT 3, 2025, View Source [SID1234656421]). The Phase 2 trial evaluated evorpacept, the Company’s lead therapeutic candidate, in combination with HERCEPTIN (trastuzumab), CYRAMZA (ramucirumab) and paclitaxel, for patients with previously treated HER2-positive advanced gastric cancer (GC) and gastroesophageal junction (GEJ) cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details for the poster presentation at SITC (Free SITC Whitepaper) 2025 are as follows:
Title: CD47 expression as a predictive biomarker for evorpacept in HER2-positive gastric/gastroesophageal cancer from the Phase 2 randomized ASPEN-06 trial
First Author: Zev A. Wainberg, M.D., Professor of Medicine and Co-Director of GI Oncology Program, University of California, Los Angeles
Abstract: 496
Date and Time: Saturday, November 8, 2025, 10:00 a.m. – 6:35 p.m. ET
Location: Poster Hall (Exhibit Halls AB)

About ASPEN-06

ASPEN-06 is a randomized Phase 2 (open-label)/3 (blinded), international, multi-center study, evaluating evorpacept in combination with HERCEPTIN (trastuzumab), CYRAMZA (ramucirumab) and paclitaxel, for patients with metastatic second- or third-line HER2 overexpressing gastric/GEJ adenocarcinoma that has progressed on or after prior HER2-directed therapy and fluoropyrimidine- or platinum-containing chemotherapy and are suitable for chemotherapy. One hundred twenty-seven adult patients were enrolled in the Phase 2 portion of the study.